2025-07-25 08:00 Regulatory
Biovica, active in blood-based cancer monitoring, today announces the launch of DiviTum Tka for use in early breast cancer for patients undergoing adjuvant therapy, available as a laboratory developed test (LDT) from its CLIA-certified laboratory in the...
2025-07-24 08:00 Regulatory
Biovica, a leader in blood-based cancer monitoring, today announced its fourth’s work order with this Tier-1 pharmaceutical customer. This order is valued at approximately SEK 3 million. The project is expected to be fully executed during fall 2025...
2025-07-17 10:00 Regulatory
Biovica International AB (publ) ("Biovica" or the "Company") has prepared an information document (the "Information Document") in connection with the Company's fully underwritten rights issue of shares with preferential...
2025-07-14 11:00 Regulatory
Today on 14 July 2025 the extra general meeting of Biovica International AB (the "Company") was held, and the following resolutions were passed by the meeting. Amendments of the articles of associationThe extra general meeting resolved, for...
2025-06-27 08:00 Regulatory Annual
Annual Report for the finacial year 2024/2025 for Biovica International AB is published today on our website. See URL below Contact Anders Rylander, CEOPhone: +46 76 666 16 47E-mail: anders.rylander@biovica.com Anders Morén, CFOPhone: +46 73 125...
2025-06-26 08:00 Regulatory
Biovica today announced that the European Patent Office (EPO) has granted a new patent for the company’s biomarker technology in the field of immuno-oncology. The patent covers the use of TKa as a marker for predicting the efficacy of immune checkpoint...
2025-06-18 08:00 Regulatory Interim
Positive development in the USA continues Biovica in brief – Treatment decisions with greater certainty Webcast:When: 18 June 2025, 3 PM to 4 PM CETWhere: register via: https://www.eventbrite.com/e/biovica-q4-earnings-call-2024-25-tickets-1392516366939Broadcast...
2025-06-11 09:47 Regulatory
Biovica, active in blood-based cancer monitoring, has signed a new Master Service Agreement (MSA) – along with an initial Work Order of ~800 kSEK – with a Tier-1 US-based biopharmaceutical company. The new customer, a global leader in oncology...
2025-06-11 08:01 Regulatory
The shareholders of Biovica International AB, reg. no. 556774-6150 (the "Company"), are hereby invited to the extra general meeting to be held on Monday 14 July 2025, at 10:00 CET at Baker McKenzie Advokatbyrå on Vasagatan 7, 101 23 Stockholm...
2025-06-11 08:00 Regulatory
NOT TO BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, THE UNITED STATES OF AMERICA, OR ANY OTHER JURISDICTION IN WHICH SUCH ACTIONS...

>4,500

Numbers of patients in studies

28

Publications

32

Pharma Projects

Are you a US resident?

Only US residents will be able to qualify for this program

No